Recombinant Adenovirus Serotype 26 (Ad26) and Ad35 Vaccine Vectors Bypass Immunity to Ad5 and Protect Nonhuman Primates against Ebolavirus Challenge

Prime-boost vectored malaria vaccines: Progress and prospects

(2010) Adrian V. S. Hill et al.   Human vaccines & immunotherapeutics

CD8+ T Cell Responses following Replication-Defective Adenovirus Serotype 5 Immunization Are Dependent on CD11c+ Dendritic Cells but Show Redundancy in Their Requirement of TLR and Nucleotide-Binding Oligomerization Domain-Like Receptor Signaling

(2010) R. W. B. Lindsay et al.   JOURNAL OF IMMUNOLOGY

A Phase 1/2 Study of a Multiclade HIV‐1 DNA Plasmid Prime and Recombinant Adenovirus Serotype 5 Boost Vaccine in HIV‐Uninfected East Africans (RV 172)

(2010) Hannah Kibuuka et al.   JOURNAL OF INFECTIOUS DISEASES

Vector Choice Determines Immunogenicity and Potency of Genetic Vaccines against Angola Marburg Virus in Nonhuman Primates

(2010) T. W. Geisbert et al.   JOURNAL OF VIROLOGY

Priming Immunization with DNA Augments Immunogenicity of Recombinant Adenoviral Vectors for Both HIV-1 Specific Antibody and T-Cell Responses

(2010) Richard A. Koup et al.   PLoS One

Safety and Immunogenicity of a Replication-Defective Adenovirus Type 5 HIV Vaccine in Ad5-Seronegative Persons: A Randomized Clinical Trial (HVTN 054)

(2010) Laurence Peiperl et al.   PLoS One

Prospects for immunisation against Marburg and Ebola viruses

(2010) Thomas W. Geisbert et al.   REVIEWS IN MEDICAL VIROLOGY

Stabilizing formulations for inhalable powders of an adenovirus 35-vectored tuberculosis (TB) vaccine (AERAS-402)

(2010) Tom H. Jin et al.   VACCINE

A replication defective recombinant Ad5 vaccine expressing Ebola virus GP is safe and immunogenic in healthy adults

(2010) J.E. Ledgerwood et al.   VACCINE

Safety and Immunogenicity of the Merck Adenovirus Serotype 5 (MRKAd5) and MRKAd6 Human Immunodeficiency Virus Type 1 Trigene Vaccines Alone and in Combination in Healthy Adults

(2009) C. Harro et al.   Clinical and Vaccine Immunology

Comparative Cell‐Mediated Immunogenicity of DNA/DNA, DNA/Adenovirus Type 5 (Ad5), or Ad5/Ad5 HIV‐1 Clade BgagVaccine Prime‐Boost Regimens

(2009) David M. Asmuth et al.   JOURNAL OF INFECTIOUS DISEASES

New Insights on Adenovirus as Vaccine Vectors

(2009) Marcio O Lasaro et al.   MOLECULAR THERAPY

Correlates of protective immunity for Ebola vaccines: implications for regulatory approval by the animal rule

(2009) Nancy J. Sullivan et al.   NATURE REVIEWS MICROBIOLOGY

Heterologous prime/boost immunizations of rhesus monkeys using chimpanzee adenovirus vectors

(2009) Sampa Santra et al.   VACCINE

Evaluation of a prime-boost vaccine schedule with distinct adenovirus vectors against malaria in rhesus monkeys

(2009) Ariane Rodríguez et al.   VACCINE

International epidemiology of human pre-existing adenovirus (Ad) type-5, type-6, type-26 and type-36 neutralizing antibodies: Correlates of high Ad5 titers and implications for potential HIV vaccine trials

(2009) T. Christopher Mast et al.   VACCINE

Magnitude and Phenotype of Cellular Immune Responses Elicited by Recombinant Adenovirus Vectors and Heterologous Prime-Boost Regimens in Rhesus Monkeys

(2008) J. Liu et al.   JOURNAL OF VIROLOGY

Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial

(2008) Susan P Buchbinder et al.   LANCET

Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys

(2008) Jinyan Liu et al.   NATURE

Adenovirus 5 and 35 vectors expressing Plasmodium falciparum circumsporozoite surface protein elicit potent antigen-specific cellular IFN-γ and antibody responses in mice

(2008) Joseph P. Shott et al.   VACCINE